GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: CM-082 | CM082 | Example 8 [WO2008033562A2] | EYP-1901 | X-82
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Vorolanib (CM082) is a potent and selective, oral clinical stage multi-kinase inhibitor. Targets include all VEGFR isoforms, PDGFR and CSF1R. [1-3]. It is a structural derivative of sunitinib. Vorolanib has anti-angiogenic activity, and is being investigated for anti-tumour effects and utility to treat ocular neovascularisation.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| CM082 inhibits proliferation, migration and invasion of HUVECs in vitro, via a VEGFR2-dependent mechanism [1]. The original patent claims for CM082 do not provide quantitiative potency data for target inhibition. |